Xellia Pharmaceuticals ('Xellia') is a global leader in providing critical care therapies and anti-infective treatments against serious and often life-threatening infections; ranging from Active Pharmaceutical Ingredients (APIs) to drug products (FDFs), and from generics to specialty pharmaceuticals. Customers depend on us for reliable supply and consistent quality, and to exemplify responsible manufacturing, production, and research and development that promote long-term sustainability. Headquartered in Copenhagen, Denmark and owned by Novo Holdings A/S, Xellia Pharmaceuticals has more than 1800 employees globally. From state-of-the-art manufacturing sites in the U.S., China, Denmark and Hungary to R&D sites in Norway and Croatia and commercial operations across Europe, Asia, the Middle East and North America; Xellia Pharmaceuticals’ strong market position is built on more than 120 years of pharmaceutical industry experience. With the patient in focus, Xellia is building a pipeline of value-added critical care therapies which aim to enhance patient care by providing convenience and ease of use for healthcare professionals.